8,9 On the basis of these encouraging clinical data and the stimulating experimental data, OPG has been proposed to represent the long sought for link between osteoporosis and arterial diseases, explaining the common coincidence of both disorders. 7 Two cross-sectional evaluations demonstrated a relation between OPG level and severe coronary atherosclerosis in predominantly male subjects. A prospective study in elderly women yielded the first epidemiological evidence of an association between OPG and both fatal stroke and overall vascular mortality. Very recently, osteoprotegerin (OPG), a key factor in bone remodeling, 5 a member of the tumor necrosis factor (TNF) receptor family, and a decoy receptor for the receptor activator of nuclear factor-κB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL), 6 was implicated in human atherogenesis. 1–4 Some of these concepts may well give rise to new approaches in prevention or provide access to routine assessment of personal vascular risks and may be relevant to the efficacious application of the risk-lowering strategies currently available. In recent years, our understanding of the pathological processes underlying atherosclerosis has been enriched by several promising hypotheses about new risk conditions such as infectious agents, inflammatory and immune processes, or iron overload, to list just a few. Furthermore, a high level of osteoprotegerin was an independent risk factor for incident cardiovascular disease (adjusted relative risk for the top versus bottom tertile group for osteoprotegerin 2.2 P=0.001) and vascular mortality (adjusted relative risk for the top versus bottom tertile group for osteoprotegerin 3.1 P=0.010) but not for mortality due to nonvascular causes.Ĭonclusions- Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. In multivariate analyses, osteoprotegerin was significantly related to severity and 10-year progression of carotid atherosclerosis. Serum osteoprotegerin showed a strong association with numerous vascular risk factors, including age, diabetes, markers of systemic inflammation, chronic infection, and smoking. Osteoprotegerin levels were measured in samples obtained at baseline and during follow-up. Cases of incident cardiovascular disease and vascular mortality were carefully recorded over a 10-year period (1990 to 2000). Methods and Results- As part of the prospective, population-based Bruneck Study, severity, initiation, and progression of atherosclerosis were assessed in carotid arteries. Recent experimental research has implicated osteoprotegerin in atherogenesis, but epidemiological confirmation of this concept is sparse. Customer Service and Ordering Informationīackground- Osteoprotegerin is a novel member of the tumor necrosis factor receptor superfamily and a soluble decoy receptor of the receptor activator of nuclear factor-κB ligand.Stroke: Vascular and Interventional Neurology.Journal of the American Heart Association (JAHA). Circ: Cardiovascular Quality & Outcomes.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |